We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum antivenom for snakebites. Conventional antivenom is outdated: it's expensive, labor-intensive, works for a single species of snake, can only be administered in a hospital, must be kept cold, and has a host of negative side effects for the patient. Our first product, Vipax, elegantly solves these problems while being cheaper to produce. Source
No articles found.
Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company developing novel p...
Evogene (NASDAQ, TASE: EVGN) is a leading biote...
Axovant is accelerating the development of innovative gene therapy products that a...
Axovant is accelerating the development of inno...
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic a...
Lipocine Inc. is a clinical-stage biopharmaceut...
Neos Therapeutics develops, manufactures, and commercializes innovative extended-r...
Neos Therapeutics develops, manufactures, and c...
Join the National Investor Network and get the latest information with your interests in mind.